Alexandra Sorvina

Dr. Alexandra Sorvina

Mechanisms in Cell Biology and Disease Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, City East Campus, University of South Australia, SA 5001, Australia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
Shane HickeyShane Hickey
Shane Hickey
BUBenjamin Ung
Benjamin Ung
CBChristie Bader
Christie Bader
Robert Douglas BrooksRobert Douglas Brooks
Robert Douglas Brooks
JLJoanna Lazniewska
Joanna Lazniewska
Doug BrooksDoug Brooks
Doug Brooks
Fluorescence microscopy has become a critical tool for researchers to understand biological processes at the cellular level. Micrographs from fixed and live-cell imaging procedures feature in a plethora of scientific articles for the field of cell biology, but the complexities of fluorescence microscopy as an imaging tool can sometimes be overlooked or misunderstood. This review seeks to cover the three fundamental considerations when designing fluorescence microscopy experiments: (1) hardware availability; (2) amenability of biological models to fluorescence microscopy; and (3) suitability of imaging agents for intended applications. This review will help equip the reader to make judicious decisions when designing fluorescence microscopy experiments that deliver high-resolution and informative images for cell biology.

2 December 2019 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
JDJack R. T. Darby
Jack R. T. Darby
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
CBChristie A. Bader
Christie A. Bader
MLMitchell C Lock
Mitchell C Lock
JSJia Yin Soo
Jia Yin Soo
JMJanna Morrison
Janna Morrison

1 July 2021 in Inorganic Chemistry
Verified
Journal Article
Closed access
TGTodd A. Gillam
Todd A. Gillam
CCChiara Caporale
Chiara Caporale
Robert Douglas BrooksRobert Douglas Brooks
Robert Douglas Brooks
CBChristie A. Bader
Christie A. Bader
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
SPSally Plush
Sally Plush

16 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JLJessica M Logan
Jessica M Logan
AHAshley Hopkins
Ashley Hopkins
CMCarmela Martini
Carmela Martini
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
PTPrerna Tewari
Prerna Tewari
Doug BrooksDoug Brooks
Doug Brooks
Gleason scoring is used within a five-tier risk stratification system to guide therapeutic decisions for patients with prostate cancer. This study aimed to compare the predictive performance of routine H&E or biomarker-assisted ISUP (International Society of Urological Pathology) grade grouping for assessing the risk of biochemical recurrence (BCR) and clinical recurrence (CR) in patients with prostate cancer. This retrospective study was an assessment of 114 men with prostate cancer who provided radical prostatectomy samples to the Australian Prostate Cancer Bioresource between 2006 and 2014. The prediction of CR was the primary outcome (median time to CR 79.8 months), and BCR was assessed as a secondary outcome (median time to BCR 41.7 months). The associations of (1) H&E ISUP grade groups and (2) modified ISUP grade groups informed by the Appl1, Sortilin and Syndecan-1 immunohistochemistry (IHC) labelling were modelled with BCR and CR using Cox proportional hazard approaches. IHC-assisted grading was more predictive than H&E for BCR (C-statistic 0.63 vs. 0.59) and CR (C-statistic 0.71 vs. 0.66). On adjusted analysis, IHC-assisted ISUP grading was independently associated with both outcome measures. IHC-assisted ISUP grading using the biomarker panel was an independent predictor of individual BCR and CR. Prospective studies are needed to further validate this biomarker technology and to define BCR and CR associations in real-world cohorts.

5 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
TSTetyana Shandala
Tetyana Shandala
SWShudong Wang
Shudong Wang
DSDavid J Sharkey
David J Sharkey
EPEmma Parkinson-Lawrence
Emma Parkinson-Lawrence
Doug BrooksDoug Brooks
Doug Brooks
Innate immunity is critical for host defence against pathogen and environmental challenge and this involves the production and secretion of immune mediators, such as antimicrobial peptides and pro-inflammatory cytokines. However, when dysregulated, innate immunity can contribute to multifactorial diseases, including inflammatory rheumatic disorders, type 2 diabetes, cancer, neurodegenerative and cardiovascular diseases and even septic shock. During an innate immune response, antimicrobial peptides and cytokines are trafficked via Rab11 multivesicular endosomes, and then sorted into Rab11 vesicles for traffic to the plasma membrane and secretion. In this study, a cyclin-dependent kinase inhibitor CDKI-73 was used to determine its effect on the innate immune response, based on previously identified targets for this compound. Our results showed that CDKI-73 inhibited the delivery of Rab11 vesicles to the plasma membrane, resulting in the accumulation of large multivesicular Rab11 endosomes near the cell periphery. In addition to the effect on endosome delivery, CDKI-73 down-regulated the amount of innate immune cargo, including the antimicrobial peptide Drosomycin and pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFα). We concluded that CDKI-73 has the potential to regulate the delivery and secretion of certain innate immune cargo, which could be used to control inflammation.

Verified
Journal Article
Open access
PDF file
Ian JohnsonIan Johnson
Ian Johnson
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
JLJessica M Logan
Jessica M Logan
CMCourtney Rose Moore
Courtney Rose Moore
JHJessica Heatlie
Jessica Heatlie
Doug BrooksDoug Brooks
Doug Brooks
Syntenin-1 is an essential multi-functional adaptor protein, which has multiple roles in membrane trafficking and exosome biogenesis, as well as scaffolding interactions with either the actin cytoskeleton or focal adhesions. However, how this functional multiplicity relates to syntenin-1 distribution in different endosome compartments or other intracellular locations and its underlying involvement in cancer pathogenesis have yet to be fully defined. To help facilitate the investigation of syntenin-1 biology, we developed two specific monoclonal antibodies (Synt-2C6 and Synt-3A11) to spatially distinct linear sequence epitopes on syntenin-1, which were each designed to be unique at the six-amino acid level. These antibodies produced very different intracellular staining patterns, with Synt-2C6 detecting endosomes and Synt-3A11 producing a fibrillar staining pattern suggesting a cytoskeletal localisation. Treatment of cells with Nocodazole altered the intracellular localisation of Synt-3A11, which was consistent with the syntenin-1 protein interacting with microtubules. In prostate tissue biopsies, Synt-3A11 defined atrophy and early-stage prostate cancer, whereas Synt-2C6 only showed minimal interaction with atrophic tissue. This highlights a critical need for site-specific antibodies and a knowledge of their reactivity to define differential protein distributions, interactions and functions, which may differ between normal and malignant cells.